The US government is preparing on a large scale for a booster campaign in the fall. More than 100 million doses of BioNTech/Pfizer vaccine have been ordered. Depending on the approval of the authorities, the delivery could also include a new preparation against the omicron variant.
The US government is buying additional vaccine doses of the corona vaccine from the US pharmaceutical giant Pfizer and its German partner company BioNTech. Specifically, it is about at least 105 million doses and a contract volume of over 3.2 billion dollars (3.1 billion euros), the companies and the government announced this week. Deliveries are due to begin in late summer and will include vaccines for both adults and children.
Like from one Message According to Pfizer, the contract also includes an option to purchase up to an additional 195 million vaccine doses.
According to the US pharmaceutical giant, the delivery could also include doses of the new vaccine, which should also protect against the omicron variant of the corona virus. This is currently being examined by the responsible authorities. Pfizer CEO Albert Bourla said of the completed deal:
“As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that can provide protection against current and future variants.”
Vaccines are and will remain critical to protecting people of all ages from COVID-19, Pfizer said. Bourla underscored:
“We remain proud of our longstanding partnership with the US government in fighting this pandemic and the continued good results of immunization campaigns in the United States and around the world.”
The USA is planning another booster campaign for the fall. This agreement will “provide additional doses for US citizens and help manage the next wave of COVID-19,” said BioNTech CEO Sean Marett. He added: “Subject to regulatory approval,” the shipment will also include an omicron-adapted vaccine, “which we believe is important to combat this rapidly spreading omicron variant.”
The companies said they submitted “crucial data” on the “safety” and “tolerability” of two Omicron-adapted vaccine candidates to the US Food and Drug Administration (FDA) last weekend. Even before approval was granted, the company had already started manufacturing cans of both candidates in order to “be able to start deliveries quickly after approval”.
According to UNICEF, the mRNA-based corona vaccine developed by Pfizer and BioNTech is one of the most widely used and has been officially approved in more than 110 countries worldwide. The sale of the vaccine brought both pharmaceutical companies billions in profits. There could be a few more soon. As daily News.of reported, liege the average price per vaccine dose in the new contract is more than $30, more than 50 percent higher than in the US government’s first contract with Pfizer. Back then were loud tagesschau.de $19.50 per dose has been agreed. According to this, part of the vaccine for adults should be delivered in single doses, which increases the price in production. At the same time, the aim is to reduce the number of doses of vaccines that are thrown away and not used.
more on the subject – Pfizer boss Bourla on his corona vaccine: “Had little experience with mRNA vaccines”